deTACE间隔时间86天.pdf
文本预览下载声明
CLINICAL STUDY
Transcatheter Arterial Chemoembolization with
Doxorubicin-Eluting Superabsorbent Polymer
Microspheres in the Treatment of Hepatocellular
Carcinoma: Midterm Follow-up
Jeroen Dekervel, MD, Hannah van Malenstein, MD, PhD,
Vincent Vandecaveye, MD, PhD, Frederik Nevens, MD, PhD,
Jos van Pelt, Dr, Ing, Sam Heye, MD, PhD, Wim Laleman, MD, PhD,
Werner Van Steenbergen, MD, PhD, Johan Vaninbroukx, MD,
Chris Verslype, MD, PhD, and Geert Maleux, MD, PhD
ABSTRACT
Purpose: To investigate prospectively the safety, tolerability, and efficacy of transarterial chemoembolization using super-
absorbent polymer (SAP) microspheres loaded with doxorubicin for the treatment of hepatocellular carcinoma (HCC).
Materials and Methods: During the years 2006–2011, 64 patients underwent 144 transarterial chemoembolization with SAP
microspheres procedures. Most of the patients were staged as Barcelona Clinic Liver Cancer class B (65%). The most frequent
underlying liver diseases were hepatitis C (35%) and alcoholic liver disease (28%) resulting in Child-Pugh A (73.4%) or Child-
Pugh B (17%) liver cirrhosis. Tumor response was assessed using modified Response Evaluation Criteria in Solid Tumors with
magnetic resonance (MR) imaging performed 4–6 weeks after each procedure.
Results: Serious adverse events (n ¼ 9) were ischemic or infectious in nature. Transarterial chemoembolization with SAP
microspheres resulted in objective response rates of 67.5%, 44.5%, and 25% after first, second, and third sessions. There were 16
patients (25%) who underwent orthotopic liv
显示全部